Shelf Life of Ready-to-Inject Semaglutide
Storage and Stability Information
The provided evidence does not contain specific shelf life or storage stability data for ready-to-inject semaglutide formulations. The clinical trial literature and guidelines focus exclusively on cardiovascular outcomes, efficacy, and safety profiles rather than pharmaceutical storage parameters.
What the Evidence Does NOT Address
The available studies 1, 2, 3, 4, 5, 6, 7 discuss:
- Cardiovascular outcomes in patients with type 2 diabetes 1, 4
- Dosing regimens (once-weekly subcutaneous administration at 0.5 mg or 1.0 mg, with newer 7.2 mg formulations) 4, 5
- Safety profiles including gastrointestinal adverse events 3, 4
- Clinical efficacy for glycemic control and weight reduction 5, 7
None of these sources provide pharmaceutical stability data, expiration dating, or storage requirements for the ready-to-inject pen formulations.
Clinical Guidance for Obtaining This Information
For accurate shelf life information, consult:
- The FDA-approved prescribing information (package insert) that accompanies each semaglutide product (Ozempic®, Wegovy®, or Rybelsus® for oral formulation)
- The manufacturer's product labeling printed on the medication packaging
- Pharmacy dispensing information provided with each prescription
Typical storage considerations for GLP-1 receptor agonists (based on general pharmaceutical knowledge, not from the provided evidence):
- Refrigerated storage requirements before first use
- Room temperature stability after pen is in use
- Protection from light and freezing
- Specific expiration dating that varies by formulation
The absence of this information in clinical guidelines 1 reflects that storage parameters are product-specific pharmaceutical data rather than clinical practice recommendations.